We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Becton Dickinson and Company | NYSE:BDX | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.91 | -0.39% | 234.09 | 235.52 | 234.02 | 235.00 | 309,294 | 15:57:04 |
From May 2023 to May 2024
By Sabela Ojea
Becton Dickinson said revenue rose in the latest quarter amid commercial launches, sales and 510k Food and Drug Administration clearances.
The medical technology company posted a net profit for the fiscal third quarter ended June 30 of $407 million, or $1.36 a share, compared with $390 million, or $1.18 a share, for the same period a year ago.
Stripping out one-time items, the company's earnings per share came in at $2.96. Analysts surveyed by FactSet had forecast lower adjusted earnings per share of $2.90.
Revenue rose 5.1% to $4.9 billion, beating analysts expectations of $4.84 billion, according to FactSet.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
August 03, 2023 07:05 ET (11:05 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Becton Dickinson Chart |
1 Month Becton Dickinson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
